QIAGEN (NYSE:QGEN) Vs. BIIB, SGEN, TECH, RGEN, ARGX, XLRN, NVAX, NBIX, CRSP, and EXEL
Should you be buying QIAGEN stock or one of its competitors? The main competitors of QIAGEN include Biogen (BIIB), Seagen (SGEN), Bio-Techne (TECH), Repligen (RGEN), argenx (ARGX), Acceleron Pharma (XLRN), Novavax (NVAX), Neurocrine Biosciences (NBIX), CRISPR Therapeutics (CRSP), and Exelixis (EXEL). These companies are all part of the "biological products, except diagnostic" industry.
QIAGEN vs.
Seagen (NASDAQ:SGEN) and QIAGEN (NYSE:QGEN) are both large-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, institutional ownership, community ranking, dividends, valuation, analyst recommendations, profitability, media sentiment and risk.
In the previous week, QIAGEN had 7 more articles in the media than Seagen. MarketBeat recorded 13 mentions for QIAGEN and 6 mentions for Seagen. Seagen's average media sentiment score of 0.32 beat QIAGEN's score of 0.20 indicating that Seagen is being referred to more favorably in the media.
88.2% of Seagen shares are owned by institutional investors. Comparatively, 52.2% of QIAGEN shares are owned by institutional investors. 27.6% of Seagen shares are owned by insiders. Comparatively, 9.0% of QIAGEN shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Seagen has a beta of 0.82, meaning that its share price is 18% less volatile than the S&P 500. Comparatively, QIAGEN has a beta of 0.21, meaning that its share price is 79% less volatile than the S&P 500.
Seagen has a net margin of 25.06% compared to QIAGEN's net margin of 21.92%. QIAGEN's return on equity of 21.31% beat Seagen's return on equity.
Seagen received 479 more outperform votes than QIAGEN when rated by MarketBeat users. Likewise, 67.04% of users gave Seagen an outperform vote while only 62.26% of users gave QIAGEN an outperform vote.
Seagen presently has a consensus price target of $179.56, indicating a potential upside of 2.83%. QIAGEN has a consensus price target of $52.27, indicating a potential downside of 2.20%. Given Seagen's higher possible upside, equities analysts plainly believe Seagen is more favorable than QIAGEN.
Seagen has higher revenue and earnings than QIAGEN. QIAGEN is trading at a lower price-to-earnings ratio than Seagen, indicating that it is currently the more affordable of the two stocks.
Summary
Seagen beats QIAGEN on 14 of the 18 factors compared between the two stocks.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding QGEN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment >-1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
QIAGEN (NYSE:QGEN) vs. Its Competitors
QIAGEN Competitors List
